The authors knocked down JIP4 or JNK2 via siRNA and used the JNK2 inhibitor SP600125 in addition to cetuximab treatment and achieved enhanced tumor cell radiosensitization in an additive manner as compared to single inhibition (38). Here, MAPK9 is linked to neoplasm.